In Unanimous Decision, Fed Appeals Court Reverses Lower Court Ruling and Allows 340B Antitrust Lawsuit Against Insulin Drugmakers to Advance - 340B Report

In Unanimous Decision, Fed Appeals Court Reverses Lower Court Ruling and Allows 340B Antitrust Lawsuit Against Insulin Drugmakers to Advance - 340B Report

A federal appeals court ruled unanimously Wednesday that an antitrust class action lawsuit, in which two health clinics alleged four major drugmakers had illegally colluded to deny 340B pricing on insulin and other diabetes medicines through contract pharmacy restrictions, can continue in district court—a ruling which the health centers’ attorney described as “a watershed moment for safety-net providers.”